Starting July 2026, some qualifying Medicare patients may gain access to medications like Wegovy® and Zepbound® through the new Medicare GLP-1 Bridge Program.
About the Program
For the first time, Medicare is preparing to extend coverage for GLP-1 weight loss medications, a category of drugs that have transformed obesity care. The Medicare GLP-1 Bridge Program, launching July 1, 2026, is designed to expand access for eligible beneficiaries who meet specific health criteria.
This is not automatic enrollment. Patients must meet clinical eligibility requirements, work with a qualified provider, and complete prior authorization. Weight Loss NP is here to help you navigate every step.
July 1, 2026, with coverage administered through CMS and eligible Medicare Part D plans.
May include Wegovy® (semaglutide) and Zepbound® KwikPen (tirzepatide), subject to formulary and CMS approval.
Eligibility is not automatic. A provider review and clinical documentation are required for approval.
Qualifying patients may receive name-brand GLP-1 medications like Wegovy® and Zepbound® for as low as $50/month through their Medicare benefit.
Coverage and eligibility requirements are determined by CMS and may change. This page is updated as new information becomes available.
Eligibility Factors
Qualification is based on a combination of medical factors, not a single diagnosis. Below are conditions that may support eligibility under the Medicare GLP-1 Bridge Program guidelines.
Obesity is a primary qualifying factor for GLP-1 coverage.
History of cardiovascular disease or coronary artery disease.
Elevated blood sugar that has not yet progressed to Type 2 diabetes.
Hypertension that is treated or documented in your medical record.
History of stroke or transient ischemic attack (TIA).
Diagnosed obstructive sleep apnea with documented treatment history.
Stage 2 or higher CKD as documented by your primary care provider.
Our Approach
Our nurse practitioner-led practice specializes in GLP-1 medication management and metabolic health. We guide Medicare patients through the full process, from eligibility screening to ongoing medical supervision.
A thorough clinical review to assess your eligibility based on your health history and current conditions.
We handle the documentation and clinical paperwork required to submit your prior authorization request.
Medication works best alongside structured habits. We provide coaching to support nutrition, movement, and long-term success.
Continuous monitoring, dosing adjustments, and compassionate support throughout your treatment.
Weight Loss NP is a small, Colorado-based telehealth practice dedicated to medical weight loss, GLP-1 medication management, and metabolic health. Founded and led by Katie Sorensen, NP-C, the practice provides evidence-based, compassionate care to patients across Colorado, Utah, and Florida. We are not a large clinic or a corporate health system. We are a specialized, provider-led practice focused entirely on helping patients achieve lasting results.
2-Minute Screening
Our quick Medicare GLP-1 screening quiz can help determine whether you may meet current eligibility guidelines. No commitment required.
Takes about 2 minutes. Your information is private and secure.
Priority Access
Get notified when scheduling opens and receive updates about Medicare GLP-1 coverage and qualification requirements. Waitlist members receive priority access when the program launches.
Your information is private and will never be sold.
Common Questions
This page is for informational purposes only and does not constitute medical advice, insurance advice, or a guarantee of coverage or program enrollment. Weight Loss NP is not affiliated with CMS, Medicare, Novo Nordisk, or Eli Lilly. All program details are based on publicly available information as of the date of publication and are subject to change without notice.
Eligibility for the Medicare GLP-1 Bridge Program, including medication coverage and prior authorization approval, is determined solely by CMS and your Medicare Part D plan administrator. Meeting one or more eligibility criteria does not guarantee enrollment, coverage, or medication access.
The information on this page does not establish a provider-patient relationship. Always consult with your licensed healthcare provider before making changes to your medical treatment. Wegovy® is a registered trademark of Novo Nordisk. Zepbound® is a registered trademark of Eli Lilly and Company.
Weight Loss NP is a Colorado-based medical weight loss telehealth practice specializing in GLP-1 medications, Medicare coverage guidance, and obesity medicine. Starting July 2026, qualifying Medicare patients may access name-brand GLP-1 weight loss medications including Wegovy and Zepbound through the Medicare GLP-1 Bridge Program. Eligibility factors include BMI over 35, heart disease, prediabetes, high blood pressure, sleep apnea, prior stroke, and chronic kidney disease. Weight Loss NP provides prior authorization support, medical evaluation, and ongoing GLP-1 medication management for Medicare patients in Colorado, Utah, and Florida. Founded by Katie Sorensen, NP-C.